Multidisciplinary research for molecular mechanism of cancer progression and development of diagnostic and therapeutic tool
癌症进展分子机制的多学科研究及诊断和治疗工具的开发
基本信息
- 批准号:18209043
- 负责人:
- 金额:$ 32.03万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (A)
- 财政年份:2006
- 资助国家:日本
- 起止时间:2006 至 2007
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
This research project yielded the following results.1) Predictive factors for aggressive recurrence of hepatocellular carcinoma (HCC) and identification of a novel molecular target: A prognosis of HCC patients was found to depend on the mode of recurrence, and prognostic indicators were tumor differentiation, tumor size, and aurora kinase B (ARKB) which plays a key role in genome instability. ARKB is considered to be a promising molecular target for HCC treatment.2) Clinical implication of Gap junctional intercellular communication, Conexin (Cg) 43:3) Cx 43 was found to facilitate the growth of HCC, and to be a possible molecular target, and also Vitamin K 2 was found to suppress HCC growth through upregulation of Cx32 and downregulation of Cx43.4) Identification of genes responsible for carcinogenesis and development of HCC : We identified CREB3L4, INTS3, SNAPAP located at 1q 21.5) Identification of genes responsible for pancreatic cancer metastasis : We identified Gr7 which is phospholylated with FAK, thereby inducing cell invasion. We synthesized a peptide, G7-18NATE-P which inhibits phospholylation of Grb7, thereby clarifying the inhibitory effect on the peritoneal dissemination model of pancreas cancer.6) Effect of Iκ B kinase (IKKB) inhibition on pancreas cancer: SiRNA and synthesized compound, IMD-0354 for IKKB inhibitor were found to suppress the growth of pancreas cancer in the xenograft model.
1)肝细胞癌侵袭性复发的预测因素和新分子靶点的确定:肝癌患者的预后取决于复发模式,预后指标是肿瘤分化、肿瘤大小和极光激酶B(ARKB),后者在基因组不稳定中起关键作用。2)细胞间缝隙连接通讯的临床意义,Conexin(CG)43:3)Cx43被发现促进肝癌的生长,并可能是一个分子靶点,维生素K2还被发现通过上调Cx32和下调Cx43.4)抑制肝癌的生长。3)发现与肝癌发生和发展相关的基因:我们发现CREB3L4、INTS3、SNAPAP位于1Q21.5)胰腺癌转移相关基因的鉴定:我们鉴定了与FAK磷酸化的GR7,从而诱导细胞侵袭。我们合成了一种抑制GRB7磷酸化的多肽G7-18NatE-P,从而阐明了其对胰腺癌腹膜转移模型的抑制作用。6)抑制IκB激酶对胰腺癌的作用:在异种移植瘤模型中,发现siRNA和合成的化合物IMD-0354抑制了胰腺癌的生长。
项目成果
期刊论文数量(79)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Vitamin K2 suppresses malignancy of HuH7 hepatoma cells via inhibition of connexin 43
- DOI:10.1016/j.canlet.2007.12.019
- 发表时间:2008-05-08
- 期刊:
- 影响因子:9.7
- 作者:Kaneda, Makoto;Zhang, Dan;Morita, Ikuo
- 通讯作者:Morita, Ikuo
BAMCA (BAC-arraybased MCA)法による肝癌DNAメチル化遺伝子の網羅的控索
利用BAMCA(BAC-arraybased MCA)方法全面寻找肝癌DNA甲基化基因
- DOI:
- 发表时间:2007
- 期刊:
- 影响因子:0
- 作者:趙 晨;井本逸勢;井上 純田中真二;有井滋樹;田中 博;稲澤譲治.
- 通讯作者:稲澤譲治.
高密度オリゴヌクレオチド・アレイを用いた肝細胞癌における1p32-p31遺伝子増幅領域の標的遺伝子の同定
利用高密度寡核苷酸芯片鉴定肝细胞癌1p32-p31基因扩增区的靶基因
- DOI:
- 发表时间:2006
- 期刊:
- 影响因子:0
- 作者:中島知明;安居幸一郎;稲垣恭和;全圭夏;伊藤義人;谷脇雅史;有井滋樹;岡上 武.
- 通讯作者:岡上 武.
Analysis of Angiopoietin-2/Tie2 Signaling; Novel Molecular-Targeting The rapy of Hepatocellular Carcinoma.
血管生成素-2/Tie2 信号转导分析;
- DOI:
- 发表时间:2006
- 期刊:
- 影响因子:0
- 作者:S. Tanaka;T. Ochiai;M. Yasen;A. Kudo;N. Nakamura;K. Ito;K. Teramoto;S. Arii.
- 通讯作者:S. Arii.
肝細胞癌における新規18qホモ欠失領域-高密度オリゴヌクレオチド・アレイによる解析
肝细胞癌中新型 18q 纯合缺失区域 - 使用高密度寡核苷酸阵列进行分析
- DOI:
- 发表时间:2006
- 期刊:
- 影响因子:0
- 作者:安居幸一郎;中島知明;稲垣恭和;全圭夏;伊藤義人;谷脇雅史;有井滋樹;岡上 武.
- 通讯作者:岡上 武.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ARII Shigeki其他文献
ARII Shigeki的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ARII Shigeki', 18)}}的其他基金
Study on the molecular diagnosis of metastasis and recurrence and molecular targeted therapy for intractable hepato-pancreatic cancer
难治性肝胰腺癌转移复发的分子诊断及分子靶向治疗研究
- 批准号:
20249061 - 财政年份:2008
- 资助金额:
$ 32.03万 - 项目类别:
Grant-in-Aid for Scientific Research (A)
Development of molecular- targeting therapy and prediction of mode of recurrence by analysis of molecular mechanism of invasion and metastasis of hepatocellular carcinoma
肝细胞癌侵袭转移分子机制分析分子靶向治疗发展及复发模式预测
- 批准号:
16390375 - 财政年份:2004
- 资助金额:
$ 32.03万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Order-made medicine for cancer in the viewpoint of angiogenesis
从血管生成的角度进行癌症定制治疗
- 批准号:
14370379 - 财政年份:2002
- 资助金额:
$ 32.03万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Study on the improvement of liver injury by controlling sinusoidal cells and spleen
控制肝窦细胞和脾脏改善肝损伤的研究
- 批准号:
12470257 - 财政年份:2000
- 资助金额:
$ 32.03万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of novel gene therapies in the field of liver surgery
肝脏外科领域新型基因疗法的开发
- 批准号:
09557104 - 财政年份:1997
- 资助金额:
$ 32.03万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Pathophysiology of the liver and development of a novel therapeutics based on morphological and functional study on hepatic sinusoidal
肝脏的病理生理学以及基于肝窦形态和功能研究的新型疗法的开发
- 批准号:
08457322 - 财政年份:1996
- 资助金额:
$ 32.03万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Implication of hepatic sinusoidal cells in pathophysiology of the liver diseases and development of novel therapeutic strategies
肝窦细胞在肝脏疾病病理生理学中的意义及新治疗策略的开发
- 批准号:
06454383 - 财政年份:1994
- 资助金额:
$ 32.03万 - 项目类别:
Grant-in-Aid for General Scientific Research (B)
相似海外基金
The Memorial Sloan Kettering Cancer Center SPORE in Pancreas Cancer
纪念斯隆凯特琳癌症中心胰腺癌孢子
- 批准号:
10333513 - 财政年份:2022
- 资助金额:
$ 32.03万 - 项目类别:
High Throughput Screening for SCAP Inhibitors as Pancreas Cancer Therapeutics
高通量筛选 SCAP 抑制剂作为胰腺癌治疗药物
- 批准号:
10501239 - 财政年份:2022
- 资助金额:
$ 32.03万 - 项目类别:
OVERCOMING STROMAL BARRIERS TO THERAPEUTICS IN PANCREAS CANCER
克服胰腺癌治疗的间质障碍
- 批准号:
10682621 - 财政年份:2022
- 资助金额:
$ 32.03万 - 项目类别:
High Throughput Screening for SCAP Inhibitors as Pancreas Cancer Therapeutics
高通量筛选 SCAP 抑制剂作为胰腺癌治疗药物
- 批准号:
10653222 - 财政年份:2022
- 资助金额:
$ 32.03万 - 项目类别:
The Memorial Sloan Kettering Cancer Center SPORE in Pancreas Cancer
纪念斯隆凯特琳癌症中心胰腺癌孢子
- 批准号:
10706975 - 财政年份:2022
- 资助金额:
$ 32.03万 - 项目类别:
OVERCOMING STROMAL BARRIERS TO THERAPEUTICS IN PANCREAS CANCER
克服胰腺癌治疗的间质障碍
- 批准号:
10796681 - 财政年份:2022
- 资助金额:
$ 32.03万 - 项目类别:
Defining the KRAS mutation specific interactions in pancreas cancer
定义胰腺癌中 KRAS 突变的特异性相互作用
- 批准号:
10529253 - 财政年份:2021
- 资助金额:
$ 32.03万 - 项目类别:
The Ohio State University Chronic Pancreatitis Diabetes Pancreas Cancer (CPDPC) Clinical Center
俄亥俄州立大学慢性胰腺炎糖尿病胰腺癌 (CPDPC) 临床中心
- 批准号:
10471651 - 财政年份:2021
- 资助金额:
$ 32.03万 - 项目类别:
Project 2: Immune signals promoting pancreas cancer stemness and progression
项目2:促进胰腺癌干性和进展的免疫信号
- 批准号:
10187126 - 财政年份:2021
- 资助金额:
$ 32.03万 - 项目类别:
Project 2: Immune signals promoting pancreas cancer stemness and progression
项目2:促进胰腺癌干性和进展的免疫信号
- 批准号:
10704088 - 财政年份:2021
- 资助金额:
$ 32.03万 - 项目类别: